Season 6, Episode 2 - Why do we need HBV functional cure?
In this episode, the panellists will evaluate past efforts, current trials, and the evolving landscape of HBV cure research. They will also weigh the patient-friendliness of these strategies, exploring potential pathways to a cure. How will the landscape of trials and research methodologies evolve in the future to facilitate this quest?
Faculty: Ahmed Elsharkawy (Moderator), Markus Cornberg (Faculty), Dickens Theodore (GSK Representative), Su Wang (Faculty)
This EASL Studio is supported by GSK.
Related episodes:
- EASL Studio from EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challenges
- EASL Studio S4E1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?
- EASL Studio S3E9: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B —Who will be the winner, if at all?
- EASL Studio from ILC 2022: HBV/HDV Roundtable: HBV and HDV drug development – Where do we stand and where are we going?
